CAMBRIDGE, Massachusetts — AstraZeneca is making a $2-billion bet that one of oncology’s most closely watched experimental drugs could become far more valuable when paired with the company’s growing arsenal of targeted cancer medicines.
Chief Executive Pascal Soriot says Summit Therapeutics’ ivonescimab could help power what he sees as the next generation of cancer treatment: carefully designed combinations that attack tumors through several biological pathways at the same time.
That is a much bigger ambition than simply adding another immunotherapy to an already crowded market.
AstraZeneca completed a $2 billion equity investment in Summit Therapeutics on October 5, giving the British drugmaker a roughly 12% stake and helping finance a broad clinical program involving ivonescimab and AstraZeneca’s antibody-drug conjugates, or ADCs.
The companies are already preparing combinations involving gastrointestinal, lung and breast cancers.
But the real question is whether ivonescimab can do something even bigger:
become a platform around which other next-generation cancer drugs are built.
Ivonescimab attacks cancer through two pathways at once
Ivonescimab is a bispecific antibody designed to block both PD-1 and VEGF.
PD-1 is an immune checkpoint.
Cancer cells can exploit the PD-1 pathway to effectively place a brake on immune cells that would otherwise attack the tumor.
Drugs such as Merck’s blockbuster Keytruda work by blocking that pathway.
VEGF, meanwhile, promotes the formation of new blood vessels that tumors use to obtain oxygen and nutrients.
By targeting both mechanisms in one drug, ivonescimab is designed to stimulate an immune attack while also disrupting the tumor’s blood supply.
That dual mechanism is why pharmaceutical companies are paying so much attention.
AstraZeneca says PD-1/VEGF bispecifics could improve on current immunotherapies in areas including lung, breast and gastrointestinal cancers.
AstraZeneca does not want ivonescimab by itself
The most revealing part of the deal is what AstraZeneca plans to do next.
The company is not simply investing in Summit and waiting for ivonescimab sales.
It wants to combine the drug with antibody-drug conjugates, or ADCs.
ADCs are designed to behave like guided missiles.
An antibody searches for a specific marker on a cancer cell and delivers a powerful drug payload directly to that cell, theoretically allowing doctors to attack tumors more precisely while reducing exposure to healthy tissue.
AstraZeneca has built one of the pharmaceutical industry’s strongest ADC portfolios.
Its oncology strategy increasingly revolves around combining targeted ADCs with immunotherapies to produce deeper and more durable responses.
The Summit agreement gives it another immunotherapy tool to test within that strategy.
Sone-Ve will be one of the first combinations
The first major AstraZeneca-Summit program will combine ivonescimab with sonesitatug vedotin, or Sone-Ve.
Sone-Ve is an experimental antibody-drug conjugate targeting Claudin 18.2, a protein found on certain gastrointestinal tumors.
AstraZeneca recently reported positive high-level results for Sone-Ve in previously treated advanced gastric cancer, saying the drug produced a statistically significant and clinically meaningful improvement in overall survival compared with physician-selected therapy.
The company now wants to see whether combining it with ivonescimab can produce an even stronger effect.
Initial trials will focus on gastrointestinal cancers.
The scientific logic is straightforward.
Sone-Ve can directly kill tumor cells.
Ivonescimab can simultaneously activate the immune system and target tumor blood-vessel formation.
If the mechanisms complement each other, the combination could theoretically attack cancer from several directions at once.
But that remains a hypothesis until clinical trials demonstrate a meaningful benefit.
Datroway is already next in line
Only days after announcing the Summit investment, AstraZeneca and partner Daiichi Sankyo added another major combination.
The companies will test Datroway, an approved TROP2-directed antibody-drug conjugate, together with ivonescimab across multiple tumor types.
The program is expected to begin with a Phase III trial in first-line triple-negative breast cancer.
Additional studies will examine lung and other cancers.
That tells investors something important.
AstraZeneca is not treating the Summit deal as a one-drug experiment.
It is already building multiple clinical programs around ivonescimab.
Why AstraZeneca thinks combinations are the future
Cancer is difficult to treat partly because tumors evolve.
One therapy may successfully attack one biological pathway, only for the cancer to survive through another.
That has made combination therapy increasingly important in modern oncology.
Doctors already combine:
immunotherapies,
chemotherapy,
targeted therapies,
ADCs,
and other drugs.
The pharmaceutical industry’s next challenge is figuring out which combinations produce the largest survival benefit without creating unacceptable toxicity.
Soriot told CNBC that this kind of combination strategy could represent the future of cancer care.
AstraZeneca’s own oncology leadership has made a similar argument, saying ADCs could become treatment “backbones” that are paired with next-generation immunotherapies such as ivonescimab.
That would represent a major shift.
Instead of developing drugs mainly as standalone products, companies would increasingly develop platforms designed to work together.
Keytruda is the benchmark everyone wants to beat
Any discussion of ivonescimab inevitably leads to Keytruda.
Merck’s PD-1 immunotherapy has become one of the most commercially successful medicines in pharmaceutical history and is used across numerous cancers.
Ivonescimab drew enormous industry attention after Chinese trial data suggested it could outperform Keytruda in some patients with advanced non-small cell lung cancer.
But those comparisons need careful interpretation.
Some ivonescimab studies have produced very encouraging results, including improved progression-free survival in Chinese lung-cancer trials.
However, a separate late-stage study combining ivonescimab with chemotherapy showed only a trend toward better overall survival without reaching statistical significance at the reported analysis.
That means the narrative that ivonescimab has definitively “beaten Keytruda” everywhere is too simplistic.
Clinical results can vary by disease type, treatment setting, biomarker status and patient population.
The strongest data have largely come from China
Ivonescimab was originally engineered by Chinese biotechnology company Akeso.
Summit Therapeutics acquired development and commercialization rights across major markets outside China through a deal that could ultimately be worth billions of dollars.
Akeso retains rights in China and certain other territories.
Ivonescimab is already approved in China for specific non-small cell lung cancer settings and is being tested internationally in numerous late-stage studies.
The drug is currently being studied in cancers including:
non-small cell lung cancer,
small cell lung cancer,
triple-negative breast cancer,
bladder cancer,
colorectal cancer,
pancreatic cancer,
head and neck cancer,
and biliary tract cancer.
That wide development program is one of the reasons AstraZeneca was willing to invest so heavily.
The U.S. market remains crucial
Summit ultimately needs ivonescimab to succeed outside China.
The U.S. market is particularly important because oncology treatments can generate billions of dollars in annual revenue if they become standard therapies.
Ivonescimab is under U.S. regulatory review in a lung-cancer setting involving EGFR-mutated non-small cell lung cancer.
Regulatory approval would be a major validation for Summit.
But even approval in one indication would not prove that the drug works across every cancer where it is being tested.
Each combination and disease setting still needs its own clinical evidence.
That distinction is important because investors often value oncology assets based on the assumption that one successful drug can eventually spread across many indications.
Sometimes it happens.
Sometimes it does not.
AstraZeneca avoided a full acquisition
The structure of the deal is also notable.
AstraZeneca invested $2 billion in Summit but did not buy the company.
Summit continues to own its rights to ivonescimab.
Each company will also retain development and commercial rights to its own medicines in the combination programs.
That gives AstraZeneca strategic exposure without assuming the much greater risk of a multibillion-dollar takeover.
It can test ivonescimab alongside its portfolio and expand the relationship if the data are strong.
Reuters reported that analysts viewed the structure as a way for AstraZeneca to gain access to a promising mechanism while keeping strategic flexibility.
Earlier takeover speculation was far bigger
That is especially interesting because AstraZeneca had previously been linked to a much larger possible deal.
Reuters reported in 2025 that AstraZeneca and Summit had discussed a possible licensing transaction worth as much as $15 billion, according to Bloomberg sources.
That agreement never materialized in the reported form.
Instead, AstraZeneca has now chosen the more conservative path:
a $2-billion equity stake plus clinical collaborations.
That may reflect confidence in the drug—but also caution.
If ivonescimab eventually becomes a major commercial platform, AstraZeneca has positioned itself close to the asset.
If the drug disappoints, it has avoided paying the price of a full acquisition.
The move also fills a gap in AstraZeneca’s pipeline
AstraZeneca’s interest became even more strategically important after a setback involving one of its own experimental bispecific immunotherapies.
Reuters reported that the company recently discontinued volrustomig, leaving part of its solid-tumor pipeline thinner than investors had expected.
Analysts said the Summit agreement effectively gives AstraZeneca access to a promising PD-1/VEGF bispecific mechanism and puts it closer to rivals developing similar approaches.
That competitive landscape includes companies such as Merck, Bristol Myers Squibb and Pfizer.
The race is becoming one of oncology’s hottest areas.
China is becoming an increasingly important source of global drugs
Ivonescimab also highlights a much bigger pharmaceutical trend.
Western drugmakers are increasingly looking to Chinese biotechnology companies for innovative medicines.
Only days after AstraZeneca’s Summit investment, Novartis announced a potential $7.8-billion deal with China’s Abogen involving mRNA-based treatments.
Novo Nordisk separately struck a deal worth up to $2.6 billion for rights to an experimental weight-loss drug from Jiangsu Hengrui Pharmaceuticals.
The message is increasingly clear.
China is no longer merely a manufacturing base or a market for Western medicines.
Chinese biotech companies are now producing drugs that some of the world’s biggest pharmaceutical companies want to license, combine or commercialize globally.
Merck is fighting back with its own combinations
Keytruda itself is also increasingly being paired with newer cancer medicines.
Merck and China’s Kelun-Biotech recently reported that a combination of Keytruda and the ADC sacituzumab tirumotecan, or sac-TMT, reduced the risk of disease progression or death by about 65% compared with Keytruda alone in a late-stage Chinese lung-cancer trial.
Response rates reached around 70.2%, versus 42% with Keytruda alone, although overall survival data were still immature.
That result illustrates exactly why AstraZeneca is pursuing ivonescimab combinations.
The next generation of oncology competition may not be:
Drug A versus Drug B.
It could increasingly become:
Combination A versus Combination B.
Breast cancer is becoming another major battleground
The same pattern is emerging in breast cancer.
Gilead’s Trodelvy combined with Keytruda reduced the risk of disease progression by 35% compared with chemotherapy plus Keytruda in patients with advanced PD-L1-positive triple-negative breast cancer.
Median progression-free survival improved to 11.2 months versus 7.8 months.
AstraZeneca’s decision to test Datroway with ivonescimab in first-line triple-negative breast cancer therefore enters an already competitive race.
The winning regimen will need to show not only strong tumor control but also manageable side effects and meaningful survival improvement.
Combination therapy also has a downside: toxicity
More drugs do not automatically mean better treatment.
Combining powerful cancer therapies can increase side effects.
Immunotherapies can trigger the immune system to attack healthy organs.
Anti-VEGF treatments can affect blood pressure and bleeding risks.
ADCs can cause blood, lung, gastrointestinal and other toxicities depending on their payloads and targets.
Adding several mechanisms together therefore requires careful dosing and patient selection.
A combination that improves progression-free survival but causes severe toxicity may not become widely used.
This is why AstraZeneca’s enthusiasm should not be confused with clinical certainty.
Cost could become another major issue
Cancer medicines are also expensive.
A future regimen involving a bispecific immunotherapy plus an antibody-drug conjugate could potentially involve two premium-priced medicines given repeatedly.
That raises difficult questions for health systems.
Even if a combination works better, insurers and governments still need to decide whether the improvement justifies the cost.
That issue becomes especially important if these treatments move into earlier-stage disease, where patient populations are much larger.
Scientific success does not automatically guarantee broad access.
AstraZeneca is doubling down on oncology
The Summit deal comes as AstraZeneca continues pouring capital into cancer research.
On October 5, the company opened a major new R&D center in Cambridge, Massachusetts, part of a planned investment of more than $1 billion in the state and its broader $50-billion U.S. investment program.
The company expects to grow its Massachusetts workforce substantially as it expands research capabilities.
Oncology remains one of AstraZeneca’s most strategically important businesses.
Its portfolio already includes drugs such as:
Tagrisso,
Imfinzi,
Enhertu,
Datroway,
and numerous experimental ADCs.
Ivonescimab gives it another mechanism to combine with those assets.
AstraZeneca wants a network effect inside its drug portfolio
That may be the most important strategic idea behind the Summit investment.
A drug portfolio becomes more valuable when the medicines can work together.
If AstraZeneca owns a strong ADC and can pair it with a powerful immunotherapy, it can potentially create a proprietary regimen.
If several AstraZeneca ADCs work with ivonescimab, one partnership could generate many different clinical programs.
That creates a kind of network effect inside oncology research.
The commercial prize becomes much larger than one medicine.
A successful platform could produce treatments across several tumor types and multiple lines of therapy.
But ivonescimab still has to prove itself globally
The excitement around the drug is understandable.
Its mechanism is compelling.
Chinese clinical results have attracted global attention.
AstraZeneca is investing billions.
Multiple Phase III trials are underway.
But the biggest evidence still has to come.
Can the benefits seen in China be replicated in broader international populations?
Will overall survival improve significantly?
Can combinations with ADCs produce better outcomes without unacceptable toxicity?
Will regulators approve it?
And can health systems afford the resulting regimens?
Those are the questions that determine whether ivonescimab becomes a major new standard of care—or simply another promising oncology asset that falls short of enormous expectations.
The real $2-billion bet is on combinations
AstraZeneca’s Summit investment therefore should not be viewed as a simple vote of confidence in one experimental cancer drug.
It is a bet on a much larger vision of oncology.
One therapy activates the immune system.
Another cuts off the tumor’s vascular support.
A third delivers a cancer-killing payload directly into malignant cells.
Instead of relying on one mechanism, the goal is to combine several complementary ones.
That is what Soriot means when he talks about the future of cancer care.
Ivonescimab may ultimately become important not because it replaces every existing immunotherapy, but because of what doctors can combine with it.
And if AstraZeneca’s strategy works, its $2-billion investment in Summit could eventually look less like a bet on a single drug—and more like an early stake in a new generation of cancer-treatment combinations.
